EGFR外显子20插入突变阳性NSCLC治疗的临床研究进展

Epidermal growth factor receptor (EGFR) exon 20 insertion mutations are the third most prevalent activating EGFR mutation in non-small cell lung cancer (NSCLC), accounting for 5%-12% of all EGFR mutations in NSCLC cases. Patients harboring EGFR exon 20 insertion mutations exhibit similar clinical ch...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
综述
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127758/
https://www.ncbi.nlm.nih.gov/pubmed/35599009
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.103.01

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127758/
https://www.ncbi.nlm.nih.gov/pubmed/35599009
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.103.01

Ejemplares similares